 |
Discovering new drugs for Hepatocellular Carcinoma? |
|
|
67-72 |
|
|
Beyond Regorafenib for Hepatocellular Carcinoma: Next – generation Perspectives. |
|
|
73-78 |
|
|
RNA-sequencing identifies a new molecular classification of pancreatic cancer: Implications and challenges.
|
|
|
79-84 |
|
|
Predicting risk of disease and therapeutic resistance for patients with Hepatocellular Carcinoma. |
|
|
85-90 |
|
|
Predicting the efficacy of novel drugs at early stage of development. |
|
|
91-98 |
|
|
Structural genomic alterations, non-coding variants and regulatory networks. The revolution of future in cancer therapy. |
|
|
99-106 |
|
|
Overcoming challenges of primary liver cancers by integrating Next-Generation Sequencing.
|
|
|
107-121 |
|
|
Linear transcription dogma: the standard approach for drug discovery.
|
|
|
122-134 |
|
